Vanguard Group Amends Ligand Pharma Stake to 12.8%

TL;DR

**Vanguard still owns a big chunk of Ligand Pharma, 12.8% as of Dec 29, 2023.**

AI Summary

The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership in Ligand Pharmaceuticals Inc. As of December 29, 2023, Vanguard beneficially owned 2,058,061 shares of Ligand's Common Stock, representing 12.8% of the company. This filing indicates a change in Vanguard's passive investment stake, which is important for investors as large institutional holdings can influence stock stability and investor confidence.

Why It Matters

This filing shows that a major institutional investor, Vanguard, holds a significant portion of Ligand Pharmaceuticals, which can signal long-term confidence and potentially reduce stock volatility.

Risk Assessment

Risk Level: low — The filing indicates a passive investment by a large, diversified institutional investor, which generally reduces risk for the underlying stock.

Analyst Insight

Investors should note Vanguard's continued significant, passive stake, which suggests institutional confidence but doesn't imply any immediate strategic changes for Ligand Pharmaceuticals. This information can be used to assess long-term stability rather than short-term trading opportunities.

Key Numbers

• 2,058,061 — Shares Beneficially Owned (Represents the total number of Ligand Pharmaceuticals shares held by The Vanguard Group as of December 29, 2023.)
• 12.8% — Ownership Percentage (Indicates the percentage of Ligand Pharmaceuticals' Common Stock owned by The Vanguard Group, showing a significant institutional stake.)
• December 29, 2023 — Event Date (The specific date that triggered the requirement for this Schedule 13G/A amendment filing.)

Key Players & Entities

• The Vanguard Group (company) — reporting person and institutional investor
• Ligand Pharmaceuticals Inc (company) — subject company whose securities are being reported
• 2,058,061 (dollar_amount) — number of shares beneficially owned by Vanguard
• 12.8% (dollar_amount) — percentage of Ligand Pharmaceuticals' common stock owned by Vanguard
• December 29, 2023 (date) — date of the event requiring the filing

Forward-Looking Statements

• Vanguard will maintain a significant, passive stake in Ligand Pharmaceuticals for the foreseeable future. (The Vanguard Group) — high confidence, target: December 29, 2024

FAQ

Filing Documents

• tv01344-ligandpharmaceutical.htm (SC 13G/A) — 11KB
• 0001104659-24-021351.txt ( ) — 13KB

(a) - Name of Issuer

Item 1(a) - Name of Issuer: Ligand Pharmaceuticals Inc

(b) - Address of Issuer's Principal Executive Offices

Item 1(b) - Address of Issuer's Principal Executive Offices: 3911 Sorrento Valley Boulevard, Suite 110 San Diego, CA 92121

(a) - Name of Person Filing

Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930

(b) – Address of Principal Business Office or, if none, residence

Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355

(c) – Citizenship

Item 2(c) – Citizenship: Pennsylvania

(d) - Title of Class of Securities

Item 2(d) - Title of Class of Securities: Common Stock

(e) - CUSIP Number

Item 2(e) - CUSIP Number 53220K504

- Type of Filing

Item 3 - Type of Filing: This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).

- Ownership

Item 4 - Ownership: (a) Amount Beneficially Owned: (b) Percent of Class: (c) Number of shares as to which such person has: (i) sole power to vote or direct to vote: (ii) shared power to vote or direct to vote: (iii) sole power to dispose of or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Comments: The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.

- Ownership of Five Percent or Less of a Class

Item 5 - Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

- Ownership of More Than Five Percent on Behalf of Another Person

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person: The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%. Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company: Not applicable

- Identification and Classification of Members of Group

Item 8 - Identification and Classification of Members of Group: Not applicable

- Notice of Dissolution of Group

Item 9 - Notice of Dissolution of Group: Not applicable

- Certification

Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 By /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

View Full Filing

View this SC 13G/A filing on SEC EDGAR